On the afternoon of October 16, 2017, Professor Mingqi Hong (Mien-Chie Hung), a tenured professor of MD Anderson cancer center in the United States, was invited to come to our institute to gave an academic lecture entitled "Marker-guided combination therapy of PARP inhibitor and immune therapy checkpoint". Our department heads, teachers and students of our college attended the lecture, the report was chaired by Prof. Changlong Li, the party chief of secretary the college.
Prof. Hong on the Lecture
Firstly, Prof. Li Changlong introduced Prof. Hong and expressed his warm welcome to his arrival. Professor Hong introduced his achievements in combined treatment of tumor under his leadership of the laboratory, and cited the case and the chart vividly to describe c-Met phosphorylation or regulate p-PARP1 through overexpression to influence cancer cells, he revealed that PARP1 inhibitors in the treatment of triple negative breast cancer. PARP1, as a chromatin associated enzyme, is highly expressed in tumor tissues, and VEGFR3, c-Met, AXL and IGF1R, which are identified by gene knockout techniques, are potential targets for cancer treatment as a potential protein kinase that inhibits p-PARP1 and ultimately inhibits cancer. He also introduced the immune point therapy from the traditional medical point derived from the “Huang Di Nei Jing” :keep healthy, do not be evil. The inhibitory signal pathway of immune checkpoint in the immune system, PD-1 and ligand PD-L1 become immune checkpoint concern due to its important role in the disability of T cells. By regulating the activity of T cells, it systemically enhance the whole antitumor immune response. For example, mAb and STM108 inhibit the glycosylation of PD-L1, and promote the activity of T cells, so fighting against cancer cells. Finally from the righting aspects, he described about the need to increase the body's immunity, various tumor microenvironment adjustment factors causing immunosuppression, reactivation of tumor immunity of patients, kill the receptors and ligands, and even does not match the cancer cells, and promote drug combination to reduce tumor cell resistance.
After the lecture, the students and teachers enthusiastically asked questions, Prof. Mien-Chie Hung interacted positively with them, sharing academic viewpoints, and on-site atmosphere was extremely active.
The lecture aroused the great interest of the students and teachers, and also provided new ideas and methods for the research and exploration while broadening the horizons.
CV of Professor Mingqi Hong:
Professor Hong is the United States MD Anderson cancer center, a tenured professor of molecular basis of the vice president, director of the Department of molecular and Cellular Oncology breast, director of the research center of Taiwan; selected as "Central Research Institute" academician in 2002; one of the initiators and the former chairman of America Chinese Biological Sciences (SCBA), the sponsor of Cancer Cell, is the renowned authority of oncology. The main research is tumor mechanism and targeted therapy ,he also is one of the main discovery of EGFR (HER2/neu), has published SCI more than 400 papers, including Science, Cell and Nature and has published more than 30 articles as corresponding author.